On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - A placebo-controlled randomized trial

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 7, 1999, Pages 907-914

  Lind, T ^a   Havelund, T ^b   Lundell, L ^d   Glise, H ^e   Lauritsen, K ^b   Pedersen, S A ^c   Anker Hansen, O ^f   Stubberod A ^g   Eriksson, G ^h   Carlsson, R ⁱ   Junghard, O ⁱ  

^a Karnsjukhuset   (Sweden)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c Odense Universitethospital ^*  (Denmark)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e Norra Alvsborg Hospital   (Sweden)

^f Lasarettet   (Sweden)

^g Sjukhuset   (Sweden)

^h Hassle Lakemedel AB   (Sweden)

ⁱ ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; OMEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESOPHAGITIS; FEMALE; GASTROINTESTINAL ENDOSCOPY; HEARTBURN; HUMAN; LIFE TABLE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SYMPTOM; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; DENMARK; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ESOPHAGITIS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; LIFE TABLES; MALE; MIDDLE AGED; OMEPRAZOLE; PATIENT COMPLIANCE; PROTON PUMPS; SWEDEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033034891     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00564.x     Document Type: Article

References (24)

1. Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 24-9.
2. Dimenäs E, Carlsson G, Glise H, Israelsson B, Wiklund I. Relevance of norm values as part of the documentation of quality of life measurements for use in upper gastrointestinal disease. Scand J Gastroenterol 1996; 31 (Suppl. 221): 8-13.
3. Jones RH, Hungin APS, Phillips J, Mills JG. Gastro-oesophageal reflux disease in primary care in Europe: clinical presentation and endoscopic findings. Eur J Gen Pract 1995; 1: 149-54.
4. Green JRB. Is there such an entity as mild oesophagitis? Eur J Clin Pract 1993; 4: 29-34.
5. Joelsson B, Johnsson F. Heartburn - the acid test. Gut 1989; 30, 1523-5.
6. Klinkenberg-Knol EC, Jansen JMBJ, Festen HPM, Meuwissen SGM, Lamers CBHW. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet 1987; i: 349-51.
7. Sandmark S, Carlsson R, Fausa O, Lundell L. Omeprazole or ranitidine in the treatment of reflux esophagitis. Scand J Gastroenterol 1988; 23: 625-32.
8. Havelund T, Laursen LS, Skoubo-Kristensen E, Andersen BN, Pedersen SA, et al. Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial. Br Med J 1988; 296: 89-92.
9. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998; 10, 119-24.
10. Masclee AAM, de Best ACAM, de Graaf R, Cluysenaer OJJ, Jansen JBMJ. Ambulatory 24-hour pH-metry in the diagnosis of gastroesophageal reflux disease. Determination of criteria and relation to endoscopy. Scand J Gastroenterol 1990; 25: 225-30.
11. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: Efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974-9.
12. Rudd P, Ahmned S, Zachary V, Barton C, Bonduelle D. Improved compliance measures: application in an ambulatory hypertensive drug trial. Clin Pharmacol Ther 1990; 48: 676-85.
13. Dupuy HJ. The psycological general well-being (PGWB) index. In: Wenger NK, Mattson ME, Furberg CF, Elinson J, eds. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. New York: Le Jacq Publishing Inc, 1984: 170-83.
14. Dimenäs E, Glise H, Hallerbäck B, Hernqvist H, Svedlund J, Wiklund I. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 1995; 30: 1046-52.
15. Dimenäs E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol 1993; 28(Suppl. 199): 18-21.
16. Schindlbeck NE, Klauser AG, Berghammer G, Londong W, Müller-Lissner SA. Three year follow up of patients with gastro-oesophageal reflux disease. Gut 1992; 33: 1016-9.
17. Carlsson R, Galmiche J-P, Dent J, Lundell L, Frison L. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997; 11: 473-82.
18. Bate CM, Booth SN, Crowe JP, Mountford RA, Keeling PWN, et al. Omeprazale 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Gut 1995; 36: 492-8.
19. 2-antagonist: symptomatic self-care compared with maintenance treatment. Aliment Pharmacol Ther 1992; 6: 315-25.
20. Klauser AG, Voderholzer WA, Knesewitsch PA, Schindlbeck NE, Müller-Lissner SA. What is behind dyspepsia? Dig Dis Sci 1993; 38: 147-54.
21. Ghillebert G, Demeyere AM, Janssens J, Vantrappen G. How well can quantitative 24-hour intraesophageal pH monitoring distinguish various degrees of reflux disease. Dig Dis Sci 1995; 40: 1317-24.
22. Shi G, Bruley des Varannes S, Scarpignato C, Le Ruhn M, Galmiche J-P. Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut 1995; 37: 457-64.
23. Mattioli, S, Pilotti V, Spangaro M, Grigioni W, Zannoli R, et al. Reliability of 24-hour home esophageal pH monitoring in diagnosis of gastroesophageal reflux. Dig Dis Sci 1989; 34: 71-8.
24. Orlando RC. The pathogenesis of gastroesophageal reflux disease: the relationship between epithelial defense, dysmotility, and acid exposure. Am J Gastroenterol 1997; 92: 3S-5S.